Small doses of a vaccine against the H5N1 bird flu virus achieved "encouraging" preliminary results in a trial involving healthy adults, Australia's CSL Ltd. said on Friday.
[...] CSL said it hopes to be able to apply for approval of a prototype vaccine by the end of 2006, after it completes a study testing doses of 30 and 45 micrograms on 800 people ranging in age from 6 months to the very old.
CSL plans to present the full results of the trial, which involved 400 people aged between 18 and 45, at an international meeting in Hawaii in March.
CSL used an aluminum phosphate adjuvant. Other companies have found better immune responses with other adjuvants, however aluminum-based adjuvants are the only additives that are registered for approval around the world, a CSL spokeswoman said.